Related Experiment Video
Updated: Aug 9, 2026
10:17
High-throughput and Comprehensive Drug Surveillance Using Multisegment Injection-Capillary Electrophoresis-Mass Spectrometry
Published on: April 23, 2019
Similarity in drugs: reflections on analogue design
1Prestwick Chemical, Boulevard Gonthier d'Andernach, 67400 Illkirch, France. camille.wermuth@prestwickchemical.fr
Drug Discovery Today
|April 4, 2006
Summary
Novel small-molecule therapeutics predominantly arise from analogue design, capturing significant market value. Analogues are defined by structural and functional similarities to existing drug molecules, categorized into direct, structural, and functional types.
Area of Science:
- Medicinal Chemistry
- Pharmacology
- Drug Discovery
Background:
- Small-molecule therapeutics are crucial in modern medicine.
- Analogue design is a prevalent strategy in developing new drugs.
- The market value of analogue-derived drugs is substantial.
Purpose of the Study:
- To survey novel small-molecule therapeutics.
- To analyze the role and definition of drug analogues in drug discovery.
- To categorize different types of drug analogues.
Main Methods:
- Literature review and market analysis of small-molecule therapeutics.
- Definition and classification of drug analogues based on structural and functional properties.
Main Results:
- The majority of novel small-molecule therapeutics originate from analogue design.
- Analogue-derived drugs account for two-thirds of all small-molecule sales.
- Three categories of drug analogues were formally established: direct, structural, and functional analogues.
Conclusions:
- Analogue design is a highly successful and economically significant approach in small-molecule drug development.
- A clear categorization of drug analogues aids in understanding their relationships and development pathways.
- Further research into these categories can optimize drug discovery strategies.
Related Concept Videos
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:28Structure-Activity Relationships and Drug Design
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
01:26Pharmaceutical Equivalents
As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
01:14Drug Dissolution: Requirements and Profile Comparison
The acceptance criteria for dissolution profile data are anchored in Q values, representing the percentage of drug dissolved within a specified period. This assessment unfolds in three stages:First Stage: The test passes if all six drug dosage units are equal to or greater than Q plus 5%; otherwise, the sample proceeds to the second stage.Second Stage: The average of twelve units must be equal to or greater than Q, with no unit falling below Q - 15% to pass; if not, it progresses to the final...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:22Biopharmaceutical Factors Influencing Drug Product Design: Overview
Rational drug product design integrates knowledge of the drug’s physicochemical properties, formulation components, manufacturing techniques, and intended route of administration. Each factor influences the drug’s performance, including how it is released, absorbed, and eliminated in the body.The physicochemical properties of a drug—such as solubility, stability, and particle size—affect its compatibility with excipients and the choice of dosage form. Excipients, though pharmacologically...